Figures & data
Table 1. Baseline characteristics of the 279 patients included in the study.
Figure 1. Signal-to-cutoff (S/CO) antibody ratio in relation to the absence of IFN-λ4 (IFNL4rs12979860 CC) or presence of IFN-λ4 (IFNL4rs12979860 CT/TT) (A), gender (B), and gender and IFN-λ4 (C). Median and interquartile range. Statistics using Mann–Whitney U test.
![Figure 1. Signal-to-cutoff (S/CO) antibody ratio in relation to the absence of IFN-λ4 (IFNL4rs12979860 CC) or presence of IFN-λ4 (IFNL4rs12979860 CT/TT) (A), gender (B), and gender and IFN-λ4 (C). Median and interquartile range. Statistics using Mann–Whitney U test.](/cms/asset/c8f89ee2-4e98-41dc-97ad-be604921f461/igas_a_1922750_f0001_b.jpg)
Figure 2. Signal-to-cutoff (S/CO) antibody ratio in anti-HCV antibody assay in relation to absent/mild or moderate/severe interface hepatitis (Ishak grade 0–2 versus 3–4) (A), and absent/mild or moderate/severe steatosis (grade 0–1 versus 2–3) (B). Median and interquartile range. Statistics using Mann-Whitney U-test.
![Figure 2. Signal-to-cutoff (S/CO) antibody ratio in anti-HCV antibody assay in relation to absent/mild or moderate/severe interface hepatitis (Ishak grade 0–2 versus 3–4) (A), and absent/mild or moderate/severe steatosis (grade 0–1 versus 2–3) (B). Median and interquartile range. Statistics using Mann-Whitney U-test.](/cms/asset/c13361de-59d0-443e-a91b-c80407e0fa65/igas_a_1922750_f0002_b.jpg)
Table 2. Associations of baseline characteristics with anti-HCV S/CO ratio.